Trials / Completed
CompletedNCT00131261
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Valerio Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Various members of this class of drugs have shown activity in preclinical studies and in initial clinical trials of multiple myeloma and lymphoma. Furthermore, HDAC inhibitors, including PXD101, have been shown to sensitize myeloma cells to the killing effect of other chemotherapeutic agents, including dexamethasone, a well-established agent in relapsing myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PXD101 | |
| DRUG | Dexamethasone |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2007-01-01
- Completion
- 2007-06-01
- First posted
- 2005-08-18
- Last updated
- 2015-07-08
Locations
10 sites across 4 countries: United States, Denmark, Norway, United Kingdom
Source: ClinicalTrials.gov record NCT00131261. Inclusion in this directory is not an endorsement.